The market didn't appreciate Amgen 's ( AMGN 1.00%) latest clinical data update, with the biopharma's shares falling more ...

According to phase 2 study, MariTide achieved significant weight loss in individuals with obesity or overweight, with up to ...

The obesity duopoly has been pierced as Amgen positions itself to have a drug on the market in a few years. While this adds ...

New studies in JACC highlight improvements in cardiac structure and function among CABG patients, as well as changes in ...